Phase IB Study of a Galectin Inhibitor (GR-MD-02) and Pembrolizumab in Patients With Metastatic Melanoma, Non-Small Cell Lung Cancer, and Head and Neck Squamous Cell Carcinoma.

Trial Profile

Phase IB Study of a Galectin Inhibitor (GR-MD-02) and Pembrolizumab in Patients With Metastatic Melanoma, Non-Small Cell Lung Cancer, and Head and Neck Squamous Cell Carcinoma.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 13 Nov 2017

At a glance

  • Drugs GR MD 02 (Primary) ; Pembrolizumab
  • Indications Head and neck cancer; Malignant melanoma; Non-small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 13 Nov 2017 Results presented in a Galectin Therapeutics Media Release.
    • 13 Nov 2017 According to a Galectin Therapeutics media release, Three patients in cohort 2 (4 mg/kg GR-MD-02) have now been completed to add to the six patients in dose cohort 1 (2 mg/kg GR-MD-02). One patient in the first cohort had head and neck cancer, while the remaining eight patients had advanced melanoma.
    • 13 Nov 2017 According to a Galectin Therapeutics media release, data were presented at the Annual Meeting of the Society for Cancer Immunotherapy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top